Feasibility Study of BMAC Enhanced CABG

Phase 1

Terminated

Brief Summary: Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium

Detailed Description: Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium. Control subjects will undergo CABG only

Recruitment & Eligibility

Inclusion Criteria

Age> 18 years and ability to understand the planned treatment.
Patients with ischemic congestive heart failure requiring by pass surgery
Congestive heart failure with ejection fraction ≤ 40%.
Serum bilirubin, SGOT and SGPT ≤2.5 time the upper level of normal.
Serum creatinine < 3.0 or no dialysis.
NYHA performance status ≥ 3.
Negative pregnancy test (in women with childbearing potential).
Subject has read and signed the IRB approved Informed Consent form
Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery

Exclusion Criteria

Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
History of Prior Radiation Exposure for oncological treatment.
History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.
History of abnormal Bleeding or Clotting.
History of Liver Cirrhosis.
Acute Myocardial Infarction < 4 weeks from treatment date.
Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to be cancer free.
Active clinical infection being treated by antibiotics within one week of enrollment
Terminal renal failure with existing dependence on dialysis
Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
Unable to have 250cc bone marrow harvested.
Medical risk that precludes anesthesia or ASA Class 5
History of ventricular arrhythmia if AICD is not present.
History of ventricular aneurysm.
Concurrent surgery such as CABG with valve surgery.
Minimally Invasive bypass surgery
Life expectancy <6 months due to concomitant illnesses
Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day)
Patients undergoing urgent by pass surgical procedure
Patients with HGB A1C > 8.5%

Primary Outcome Measures

Name	Time	Method
Change in Cardiac Status (Classification)	Through 12 months post treatment	A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation
Safety	through 1 Year post tx	as measured by frequency and severity of adverse events

Secondary Outcome Measures

Name	Time	Method

Locations (2): The Methodist Hospital
🇺🇸
Houston, Texas, United States
University of Utah
🇺🇸
Salt Lake City, Utah, United States
The Methodist Hospital
🇺🇸Houston, Texas, United States